Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
07:10am, Tuesday, 12'th Nov 2024
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of tran
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call
04:30pm, Tuesday, 29'th Oct 2024
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
08:31am, Monday, 14'th Oct 2024
Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy
MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superi
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
08:31am, Wednesday, 25'th Sep 2024
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies
STIM Stock Likely to Gain From Updated TMS Coverage
02:31pm, Monday, 23'rd Sep 2024
Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
08:31am, Thursday, 19'th Sep 2024
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patient
NeuroStar® Releases Software Upgrades to Elevate Patient Care
08:32am, Monday, 16'th Sep 2024
Upgrades improve communication, streamline data management, and strengthen security Upgrades improve communication, streamline data management, and strengthen security
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
08:29am, Tuesday, 03'rd Sep 2024
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives
Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments
02:01pm, Tuesday, 13'th Aug 2024
Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.
Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook
01:50pm, Tuesday, 13'th Aug 2024
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.
Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
10:45am, Tuesday, 13'th Aug 2024
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.
Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript
01:59pm, Monday, 12'th Aug 2024
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Keith Sullivan - President & CEO Steve Furlong - CFO Mark Klausner - IR Conference Cal
On Monday, Neuronetics Inc. STIM, a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. GBNHF in an all-stock transaction.
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
09:26am, Monday, 12'th Aug 2024
Neuronetics (STIM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.17 per share a year ago.
